ASH 2021

Written by Nikki Meyer Edited by Lauren Weinand, M.D. This retrospective study, published in Blood, and presented at the 2021 ASH Annual Meeting & Exposition, examined pre-apheresis absolute lymphocyte count (PA-ALC) and post-transplant ALC (PT-ALC) for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who had received autologous hematopoietic stem cell transplant (auto-HCT). The researchers sought to evaluate the...

Written by Nikki Meyer Edited by Lauren Weinand, M.D. Patients with cancer are a critical group in which to analyze COVID-19 vaccine response. This observational study, published in Blood, and presented at the 2021 ASH Annual Meeting & Exposition, examined COVID-19 vaccine response in patients with non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL) who received the...

Researchers across the United States recently used an oncology simulation model to estimate the survival of patients with classical Hodgkin lymphoma (cHL) for 10 years after treatment. Specifically, the study sought to estimate the future number of patients with stage III or IV cHL who are alive and progression-free over 10 years for patients who...

A new retrospective analysis of pediatric patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL), published in Blood, will be presented at the 2021 ASH Annual Meeting & Exposition. While there is a phase 3 randomized controlled trial supporting the use of brentuximab vedotin (BV) in adults with R/R HL after receiving autologous stem cell transplantation (ASCT),...

Collaboration between US Oncology Research, The US Oncology Network (The Network), and Ontada™ from McKesson resulted in more than 30 studies being submitted by the group for the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. The studies delve into various areas of blood disorders and related treatments, including different types of lymphomas...

As part of the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, Jazz Pharmaceuticals participated in 16 new studies that will be shared at the meeting. In a press release, they highlighted particularly exciting studies related to their medications, such as Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) and Vyxeos® (daunorubicin and cytarabine), being used...

In anticipation of the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, Genmab A/S shared through a press release some of the highlights of the over 20 abstracts involving their medicines and drug development platforms, particularly with their work with epcoritamab (DuoBody®-CD3xCD20). They also announced their plan to host a Virtual R&D Update...

More than 90 abstracts feature the incorporation of Roche medicines at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition this year. In a press release from the company, Roche detailed the data of studies on multiple types of blood diseases, including different lymphomas, and shared more details about an event they are...

At the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, taking place in December 2021, almost 20 abstracts will be shared about ADCETRIS® (brentuximab vedotin), a possible therapy to combine with others for advanced stage classical Hodgkin lymphoma (cHL). In a press release, Seagen Inc. recently announced the planned presentations at ASH 2021...